Next Article in Journal
Personalized Prediction of Patient Radiation Exposure for Therapy of Urolithiasis: An Application and Comparison of Six Machine Learning Algorithms
Previous Article in Journal
The Usefulness of Questionnaires in Assessing the Risk of Obstructive Sleep Apnea in Patients in the Managed Care after Acute Myocardial Infarction Program—The Results of a Cross-Sectional Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 13
Issue 4
10.3390/jpm13040641
Review Report
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

J. Pers. Med. 2023, 13(4), 641; https://doi.org/10.3390/jpm13040641
by Takafumi Yanagisawa 1,2, Pawel Rajwa 1,3, Fahad Quhal 1,4, Tatsushi Kawada 1,5, Kensuke Bekku 1,5, Ekaterina Laukhtina 1,6, Markus von Deimling 1,7, Marcin Chlosta 1,8, Pierre I. Karakiewicz 9, Takahiro Kimura 2 and Shahrokh F. Shariat 1,6,10,11,12,13,14,*
Reviewer 2:
Harshraj Leuva
J. Pers. Med. 2023, 13(4), 641; https://doi.org/10.3390/jpm13040641
Submission received: 15 March 2023 / Revised: 3 April 2023 / Accepted: 7 April 2023 / Published: 7 April 2023
(This article belongs to the Section Clinical Medicine, Cell, and Organism Physiology)

Round 1

Reviewer 1 Report

the authors explored the interesting and perspective research channel of the Neoadjuvant Androgen Receptor Signaling Inhibitors Before Radical Prostatectomy for Non-metastatic Advanced Prostate Cancer, by conducting a Systematic Review.

The aim of the paper was well stated, the authors explained the research question clearly, the study was well-designed, and the authors presented the results in a clear and repeatable way. The english was fluent and there was no unclear paragraph. The references were adeguate and updated

Author Response

Please see the attachment.

 

Author Response File: Author Response.docx

Reviewer 2 Report

Thank you for inviting me to review the article titled “Neoadjuvant Androgen Receptor Signaling Inhibitors Before Radical Prostatectomy for Non-metastatic Advanced Prostate Cancer: A Systematic Review”

 

The authors evaluate the current evidence for ARSI before prostatectomy for Non-metastatic advanced prostate cancer.

 

The data in this review is reported accurately without distortion from the representative papers. I commend the authors for summarizing the current state of evidence for neoadjuvant therapies in non-metastatic prostate cancer.

 

Comments:

Method: Were there particular years of abstracts reviewed for ASCO or ESMO? Eg. Between 2010-2022 etc.

 

Line 246 is missing the word ‘gene’ in ERG full form

 

Line 446: ‘However, although neoadjuvant ADT has never shown a survival benefit compared  to RP alone, most ongoing RCTs set the control arm as neoadjuvant ADT only. To date, the standard of care for high-risk non-metastatic PCa is RP alone when surgical treatment  is applied. The results from this RCT will provide novel insight into the efficacy of  ARSI-based neoadjuvant therapy for non-metastatic advanced PCa, while interpretation may be controversial. ‘ - I agree with this.

Author Response

Please see the attachment.

 

Author Response File: Author Response.docx

Back to TopTop